<p>根据 Candriam S.C.A.最近向美国证券交易委员会提交的 13F 文件，该公司在 2023 年第四季度减少了对 Edgewise Therapeutics, Inc.（NASDAQ:EWTX - 免费报告）股票的持有，减持幅度为 13.8%。在此期间，该基金出售了 40,659 股后，持有 253,965 股该公司的股票。截至其最近向美国证券交易委员会提交的文件，Candriam S.C.A.持有的 Edgewise Therapeutics 的股份约占 0.27%，价值 6,781,000 美元。</p>
<p>获取 <strong>Edgewise Therapeutics</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周报 – 9/23 - 9/27</li>
</ul>
<p>其他几家对冲基金和机构投资者最近也买卖了 EWTX 的股票。Braidwell LP 在第三季度购买了 Edgewise Therapeutics 的新头寸，价值 52,267,000 美元。Janus Henderson Group PLC 在第三季度将其在 Edgewise Therapeutics 的持股增加了 74.8%。Janus Henderson Group PLC 现在持有 4,558,519 股该公司的股票，价值 121,616,000 美元，此前在上个季度又购买了 1,951,220 股。Walleye Capital LLC 在第三季度购买了 Edgewise Therapeutics 的新股份，价值约 6,466,000 美元。Ally Bridge Group NY LLC 在第三季度获得了 Edgewise Therapeutics 的新头寸，价值约 5,010,000 美元。最后，摩根大通在第三季度将其在 Edgewise Therapeutics 的持仓提高了 146.3%。摩根大通现在持有 158,506 股该公司的股票，价值 4,231,000 美元，此前在上个季度又收购了 94,147 股。</p>
<h2>Edgewise Therapeutics 的内部交易</h2>
<p>在其他消息中，内部人士 Marc Semigran 于 12 月 24 日（星期二）出售了 29,709 股该股票。股票以平均价格 29.69 美元出售，总价值为 882,060.21 美元。交易完成后，该内部人士现在直接持有 6,716 股该公司的股票，价值 199,398.04 美元。这代表了其持股的 81.56% 的减少。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席执行官 Kevin Koch 于 2 月 5 日（星期三）出售了 8,636 股该公司的股票。股票以平均价格 30.03 美元出售，总交易额为 259,339.08 美元。交易后，首席执行官现在直接持有 14,478 股该公司的股票，价值约 434,774.34 美元。这笔交易使其持股减少了 37.36%。该销售的披露可以在这里找到。内部人士在过去三个月内出售了价值 4,605,305 美元的公司股票，共计 164,545 股。24.11% 的股票由公司内部人士持有。</p>
<h2>Edgewise Therapeutics 股价下跌 0.4%</h2>
<ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
<p>NASDAQ:EWTX 周五开盘价为 28.01 美元。Edgewise Therapeutics, Inc.的 12 个月最低价为 14.90 美元，最高价为 38.12 美元。该公司的 50 日移动平均线为 26.78 美元，200 日移动平均线为 27.76 美元。该公司的市值为 26.7 亿美元，市盈率为-18.67，贝塔值为 0.22。</p>
<p>Edgewise Therapeutics（NASDAQ:EWTX - 获取免费报告）最近于 3 月 3 日（星期一）公布了其财报。该公司报告季度每股收益为（0.42 美元），低于市场共识预期的（0.39 美元）3 美分。研究分析师平均预测 Edgewise Therapeutics, Inc.在当前年度的每股收益将为-1.45 美元。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>Edgewise Therapeutics 股价飙升 50%：背后的关键原因</li>
</ul>
<p>多位股票分析师最近对 EWTX 股票发表了看法。Stifel Nicolaus 在 1 月 22 日（星期三）的一份研究报告中开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “持有” 评级，目标价为 30.00 美元。加拿大皇家银行在周二重申了 “跑赢大盘” 评级，并将 Edgewise Therapeutics 的目标价设定为 56.00 美元。Wedbush 在 11 月 8 日（星期五）将 Edgewise Therapeutics 的目标价从 44.00 美元上调至 45.00 美元，并在研究报告中给予该股票 “跑赢大盘” 评级。Scotiabank 在周五开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “行业跑赢大盘” 评级，目标价为 50.00 美元。最后，Evercore ISI 在 12 月 17 日（星期二）将 Edgewise Therapeutics 的目标价从 45.00 美元上调至 50.00 美元，并给予该公司 “跑赢大盘” 评级。一位分析师对该股票给予了持有评级，七位分析师对该股票给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 45.38 美元。</p>
<p><strong>查看我们对 EWTX 的最新分析</strong></p>
<h2>Edgewise Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Edgewise Therapeutics, Inc.是一家生物制药公司，专注于发现、开发和商业化治疗肌肉疾病的疗法。其主要产品候选药物 EDG-5506 是一种口服小分子，目前正在进行二期临床试验，旨在解决包括杜氏肌营养不良症和贝克肌营养不良症在内的肌营养不良症的根本原因。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Edgewise Therapeutics 更好</li>
<li>保护您的投资组合免受冠状病毒影响的 3 只股票</li>
<li>Myers Industries 是否准备突破？</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是抛售？</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>Broadcom 确认其人工智能前景：股票即将创下新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA"/></p>
<p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Edgewise Therapeutics 吗？</h2>
<p>在考虑 Edgewise Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Edgewise Therapeutics 并不在名单上。</p>
<p>虽然 Edgewise Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

EWTX

<p>Candriam S.C.A. 已将其在 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 的持股比例减少了 13.8%，目前持有 253,965 股，此前在第四季度出售了 40,659 股。该基金的持股价值约为 678 万美元。其他机构投资者也调整了他们的头寸，出现了显著的买入和卖出。内部交易方面，Marc Semigran 和首席执行官 Kevin Koch 进行了股票出售，内部人士最近共计出售了 164,545 股。Edgewise 的股票经历了波动，分析师提供了不同的价格目标和评级</p>

<p>Candriam S.C.A. reduced its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) by 13.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 253,965 shares of the company's stock after selling 40,659 shares during the period. Candriam S.C.A. owned approximately 0.27% of Edgewise Therapeutics worth $6,781,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>根据 Candriam S.C.A.最近向美国证券交易委员会提交的 13F 文件，该公司在 2023 年第四季度减少了对 Edgewise Therapeutics, Inc.（NASDAQ:EWTX - 免费报告）股票的持有，减持幅度为 13.8%。在此期间，该基金出售了 40,659 股后，持有 253,965 股该公司的股票。截至其最近向美国证券交易委员会提交的文件，Candriam S.C.A.持有的 Edgewise Therapeutics 的股份约占 0.27%，价值 6,781,000 美元。</p>
</div><p>Get <strong>Edgewise Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Edgewise Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 9/23 - 9/27</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 9/23 - 9/27</li>
</ul>
</div><p>Several other hedge funds and other institutional investors also recently bought and sold shares of EWTX. Braidwell LP purchased a new position in Edgewise Therapeutics during the 3rd quarter worth $52,267,000. Janus Henderson Group PLC boosted its holdings in Edgewise Therapeutics by 74.8% during the third quarter. Janus Henderson Group PLC now owns 4,558,519 shares of the company's stock worth $121,616,000 after buying an additional 1,951,220 shares in the last quarter. Walleye Capital LLC purchased a new stake in Edgewise Therapeutics during the third quarter worth about $6,466,000. Ally Bridge Group NY LLC acquired a new position in Edgewise Therapeutics during the third quarter worth about $5,010,000. Finally, JPMorgan Chase &amp; Co. raised its position in Edgewise Therapeutics by 146.3% during the third quarter. JPMorgan Chase &amp; Co. now owns 158,506 shares of the company's stock worth $4,231,000 after acquiring an additional 94,147 shares during the last quarter.</p>
<div class="lb-trans"><p>其他几家对冲基金和机构投资者最近也买卖了 EWTX 的股票。Braidwell LP 在第三季度购买了 Edgewise Therapeutics 的新头寸，价值 52,267,000 美元。Janus Henderson Group PLC 在第三季度将其在 Edgewise Therapeutics 的持股增加了 74.8%。Janus Henderson Group PLC 现在持有 4,558,519 股该公司的股票，价值 121,616,000 美元，此前在上个季度又购买了 1,951,220 股。Walleye Capital LLC 在第三季度购买了 Edgewise Therapeutics 的新股份，价值约 6,466,000 美元。Ally Bridge Group NY LLC 在第三季度获得了 Edgewise Therapeutics 的新头寸，价值约 5,010,000 美元。最后，摩根大通在第三季度将其在 Edgewise Therapeutics 的持仓提高了 146.3%。摩根大通现在持有 158,506 股该公司的股票，价值 4,231,000 美元，此前在上个季度又收购了 94,147 股。</p>
</div><h2>Insider Transactions at Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 的内部交易</h2>
</div><p>In other news, insider Marc Semigran sold 29,709 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $29.69, for a total value of $882,060.21. Following the completion of the sale, the insider now directly owns 6,716 shares of the company's stock, valued at $199,398.04. This represents a 81.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Kevin Koch sold 8,636 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $30.03, for a total transaction of $259,339.08. Following the transaction, the chief executive officer now directly owns 14,478 shares in the company, valued at approximately $434,774.34. The trade was a 37.36 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 164,545 shares of company stock valued at $4,605,305 over the last three months. 24.11% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，内部人士 Marc Semigran 于 12 月 24 日（星期二）出售了 29,709 股该股票。股票以平均价格 29.69 美元出售，总价值为 882,060.21 美元。交易完成后，该内部人士现在直接持有 6,716 股该公司的股票，价值 199,398.04 美元。这代表了其持股的 81.56% 的减少。该交易已在向证券交易委员会提交的文件中披露，可以通过此链接访问。此外，首席执行官 Kevin Koch 于 2 月 5 日（星期三）出售了 8,636 股该公司的股票。股票以平均价格 30.03 美元出售，总交易额为 259,339.08 美元。交易后，首席执行官现在直接持有 14,478 股该公司的股票，价值约 434,774.34 美元。这笔交易使其持股减少了 37.36%。该销售的披露可以在这里找到。内部人士在过去三个月内出售了价值 4,605,305 美元的公司股票，共计 164,545 股。24.11% 的股票由公司内部人士持有。</p>
</div><h2>Edgewise Therapeutics Trading Down 0.4 %</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 股价下跌 0.4%</h2>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>NASDAQ:EWTX opened at $28.01 on Friday. Edgewise Therapeutics, Inc. has a twelve month low of $14.90 and a twelve month high of $38.12. The company has a 50-day moving average of $26.78 and a 200-day moving average of $27.76. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -18.67 and a beta of 0.22.</p>
<div class="lb-trans"><p>NASDAQ:EWTX 周五开盘价为 28.01 美元。Edgewise Therapeutics, Inc.的 12 个月最低价为 14.90 美元，最高价为 38.12 美元。该公司的 50 日移动平均线为 26.78 美元，200 日移动平均线为 27.76 美元。该公司的市值为 26.7 亿美元，市盈率为-18.67，贝塔值为 0.22。</p>
</div><p>Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.03). On average, research analysts forecast that Edgewise Therapeutics, Inc. will post -1.45 earnings per share for the current year.</p>
<div class="lb-trans"><p>Edgewise Therapeutics（NASDAQ:EWTX - 获取免费报告）最近于 3 月 3 日（星期一）公布了其财报。该公司报告季度每股收益为（0.42 美元），低于市场共识预期的（0.39 美元）3 美分。研究分析师平均预测 Edgewise Therapeutics, Inc.在当前年度的每股收益将为-1.45 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>Edgewise Therapeutics 股价飙升 50%：背后的关键原因</li>
</ul>
</div><p>A number of equities analysts have recently weighed in on EWTX shares. Stifel Nicolaus assumed coverage on shares of Edgewise Therapeutics in a research report on Wednesday, January 22nd. They issued a &#34;hold&#34; rating and a $30.00 price objective for the company. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and set a $56.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday. Wedbush boosted their price objective on shares of Edgewise Therapeutics from $44.00 to $45.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 8th. Scotiabank began coverage on shares of Edgewise Therapeutics in a research note on Friday. They issued a &#34;sector outperform&#34; rating and a $50.00 target price for the company. Finally, Evercore ISI upped their price target on shares of Edgewise Therapeutics from $45.00 to $50.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, December 17th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $45.38.</p>
<div class="lb-trans"><p>多位股票分析师最近对 EWTX 股票发表了看法。Stifel Nicolaus 在 1 月 22 日（星期三）的一份研究报告中开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “持有” 评级，目标价为 30.00 美元。加拿大皇家银行在周二重申了 “跑赢大盘” 评级，并将 Edgewise Therapeutics 的目标价设定为 56.00 美元。Wedbush 在 11 月 8 日（星期五）将 Edgewise Therapeutics 的目标价从 44.00 美元上调至 45.00 美元，并在研究报告中给予该股票 “跑赢大盘” 评级。Scotiabank 在周五开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “行业跑赢大盘” 评级，目标价为 50.00 美元。最后，Evercore ISI 在 12 月 17 日（星期二）将 Edgewise Therapeutics 的目标价从 45.00 美元上调至 50.00 美元，并给予该公司 “跑赢大盘” 评级。一位分析师对该股票给予了持有评级，七位分析师对该股票给予了买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，平均目标价为 45.38 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on EWTX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 EWTX 的最新分析</strong></p>
</div><h2>Edgewise Therapeutics Profile</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.</p>
<div class="lb-trans"><p>Edgewise Therapeutics, Inc.是一家生物制药公司，专注于发现、开发和商业化治疗肌肉疾病的疗法。其主要产品候选药物 EDG-5506 是一种口服小分子，目前正在进行二期临床试验，旨在解决包括杜氏肌营养不良症和贝克肌营养不良症在内的肌营养不良症的根本原因。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Edgewise Therapeutics</li>
<li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion</li>
<li>Is Myers Industries Poised for a Breakout?</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Is BigBear.ai's 25% Plunge a False Alarm or Fire Sale?</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Broadcom Confirmed Its AI Outlook: Stock to Hit New Highs Soon</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Edgewise Therapeutics 更好</li>
<li>保护您的投资组合免受冠状病毒影响的 3 只股票</li>
<li>Myers Industries 是否准备突破？</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>BigBear.ai 的 25% 暴跌是虚惊一场还是抛售？</li>
<li>股票行业对成功投资的重要性是什么？</li>
<li>Broadcom 确认其人工智能前景：股票即将创下新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=EWTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Edgewise Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Edgewise Therapeutics 吗？</h2>
</div><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Edgewise Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Edgewise Therapeutics 并不在名单上。</p>
</div><p>While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Edgewise Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Candriam S.C.A. 减少了在 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 的股份